Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rucha S. Sane"'
Autor:
Dhruvitkumar S. Sutaria, Priya Agarwal, Kuan‐Chieh Huang, Dale R. Miles, Jacob Rotmensch, Heather Hinton, Jorge Daniel Gallo, Grozdana Rasuo, Rucha S. Sane
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 12, Pp 2989-2999 (2022)
Abstract Ipatasertib, an AKT inhibitor, in combination with prednisone and abiraterone, is under evaluation for the treatment of metastatic castration‐resistant prostate cancer (mCRPC). Hyperglycemia is an on‐target effect of ipatasertib. An open
Externí odkaz:
https://doaj.org/article/ca11a807d1734da0bdab9ef78990dd4e
Autor:
Michelle McCabe, Monica Keith-Luzzi, Jun Xu, Illeaniz King, Andrea Whitcher-Johnstone, Rucha S. Sane, Donald J. Tweedie, Yongmei Li, Nicholas Johnstone
Publikováno v:
Drug Metabolism and Disposition. 43:1612-1618
Deleobuvir is a potent inhibitor of the hepatitis C virus nonstructural protein 5B polymerase. In humans, deleobuvir underwent extensive reduction to form CD 6168. This metabolite was not formed in vitro in aerobic incubations with human liver micros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64dd087a3900fe5b76bb18ac58ab27d1
https://doi.org/10.1124/dmd.115.064477
https://doi.org/10.1124/dmd.115.064477
Autor:
Lalitha Podila, Rucha S. Sane, Qihong Huang, Jerry O. Stern, Yongmei Li, Tarik Asselah, G. Steinmann, Gerhard Nehmiz, Wulf O. Böcher, Mitchell E. Taub, Stephen Olson, Kirsten Mease, Donald J. Tweedie
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 351:403-412
Faldaprevir, an investigational agent for hepatitis C virus treatment, is well tolerated but associated with rapidly reversible, dose-dependent, clinically benign, unconjugated hyperbilirubinemia. Multidisciplinary preclinical and clinical studies we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082ed1b2129063a58afc005005249cbd
https://doi.org/10.1124/jpet.114.218081
https://doi.org/10.1124/jpet.114.218081
Autor:
Eric L. Reyner, Caroline A. Lee, Harma Ellens, Kirsten M Mease, Cory A Watson, Rucha S. Sane, Liangfu Chen, Mitchell E. Taub, Márton Jani, Brad P Hirakawa
Publikováno v:
Drug Metabolism and Disposition. 39:2093-2102
Digoxin, an orally administered cardiac glycoside cardiovascular drug, has a narrow therapeutic window. Circulating digoxin levels (maximal concentration of ∼1.5 ng/ml) require careful monitoring, and the potential for drug-drug interactions (DDI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb255ff616c4c03a727fc8dda083f781
https://doi.org/10.1124/dmd.111.040816
https://doi.org/10.1124/dmd.111.040816
Autor:
Lois Rowland, Curtis Cooper, Diane Ramsden, Naitee Ting, Donald J. Tweedie, John P. Sabo, Rucha S. Sane, Andrea Whitcher-Johnstone
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 44(3)
The drug-drug interaction (DDI) potential of deleobuvir, an hepatitis C virus (HCV) polymerase inhibitor, and its two major metabolites, CD 6168 (formed via reduction by gut bacteria) and deleobuvir-acyl glucuronide (AG), was assessed in vitro. Area-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7cf82a48258602d7b18e87228c5eb10
https://pubmed.ncbi.nlm.nih.gov/26684498
https://pubmed.ncbi.nlm.nih.gov/26684498
Publikováno v:
Toxicology in Vitro. 20:135-153
Anticancer drugs have a complex pharmacological and toxicological profile with a narrow therapeutic index. It is therefore critical to understand the factors that contribute to the marked intersubject variability in the pharmacokinetics and pharmacod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0789b2f60bb8bbdd953fb7a6d14ddb8c
https://doi.org/10.1016/j.tiv.2005.06.049
https://doi.org/10.1016/j.tiv.2005.06.049
Autor:
Arthur R. Buckley, Donna J. Buckley, Niresh Hariparsad, Pankaj B. Desai, Rucha S. Sane, Srikanth C. Nallani
Publikováno v:
The Journal of Clinical Pharmacology. 44:1273-1281
The antiretroviral agent efavirenz enhances the systemic clearance of coadministered drugs that are cytochrome P450 (CYP) 3A4 substrates. The mechanism of the apparent increase in CYP3A4 activity by efavirenz and the magnitude of change relative to o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc280a07d4e2f33d9d10b12a2b3f5ef6
https://doi.org/10.1177/0091270004269142
https://doi.org/10.1177/0091270004269142
Autor:
Donna J. Buckley, Srikanth C. Nallani, Rucha S. Sane, Bryan Goodwin, Arthur R. Buckley, Linda B. Moore, Pankaj B. Desai
Publikováno v:
Drug Metabolism and Disposition. 30:608-612
Tamoxifen is a widely utilized antiestrogen in the treatment and chemoprevention of breast cancer. Clinical studies document that tamoxifen administration markedly enhances the systemic elimination of other drugs. Additionally, tamoxifen enhances its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13557d4e44174333cc89b1449351d46
https://doi.org/10.1124/dmd.30.5.608
https://doi.org/10.1124/dmd.30.5.608
Publikováno v:
Methods in Molecular Biology ISBN: 9781627037570
New molecular entities (NMEs) are evaluated using a rigorous set of in vitro and in vivo studies to assess their safety and suitability for testing in humans. Regulatory health authorities require that therapeutic and supratherapeutic doses be admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cdc7db3f767b5bd26de8ae1326971e1
https://doi.org/10.1007/978-1-62703-758-7_22
https://doi.org/10.1007/978-1-62703-758-7_22
Publikováno v:
Journal of pharmaceutical sciences. 101(5)
Determining the interaction of a molecule with membrane transporters is challenging because of overlapping substrate and inhibitor specificities and coexpression of multiple transporters. Caco-2 and MDCK-MDR1 cells were used to evaluate the selectivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0162754a134729b2d9c347018d46369
https://pubmed.ncbi.nlm.nih.gov/22359351
https://pubmed.ncbi.nlm.nih.gov/22359351